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Association of Patient Out-of-Pocket Costs With Prescription Abandonment and
Delay in Fills of Novel Oral Anticancer Agents
Abstract
High out-of-pocket (OOP) costs may limit access to novel oral cancer medications. In a retrospective
study, nearly one third of patients whose OOP costs were $100 to $500 and nearly half of patients whose
OOP costs were more than $2,000 failed to pick up their new prescription for an oral cancer medication,
compared to 10% of patients who were required to pay less than $10 at the time of purchase. Delays in
picking up prescriptions were also more frequent among patients facing higher OOP costs.
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KEYFINDINGS
High out-of-pocket (OOP) costs may limit access to novel oral cancer medications. In a retrospective study, nearly one third
of patients whose OOP costs were $100 to $500 and nearly half of patients whose OOP costs were more than $2,000 failed
to pick up their new prescription for an oral cancer medication, compared to 10% of patients who were required to pay less
than $10 at the time of purchase. Delays in picking up prescriptions were also more frequent among patients facing higher
OOP costs.

THE QUESTION

THE FINDINGS

The number of novel oral anticancer therapies has increased considerably
in recent years, often accompanied by a high price tag. Due to an increase
in high-deductible health plans and growing use of specialty tiers with
coinsurance (as opposed to fixed copayment) requirements, many cancer
patients face high out-of-pocket (OOP) costs for these medications. Because
patients must pay the entire OOP cost for an oral prescription up front, these
costs present a unique risk that patients will delay pick-up of the prescription or
opt not to fill it at all.

Among 38,111 patients, the average OOP cost was $486; overall, 18% of
patients “abandoned” their index prescription, meaning that they did not
pick up an insurer-approved prescription for the index medication within 90
days. On average, patients who abandoned their prescription had higher
mean OOP costs ($1,397) than those who filled it ($284). Across OOP cost
categories, few patients who abandoned their prescription went on to have
prescription claims for alternate cancer treatments, including intravenous
therapies, in the following 90 days.

To better understand how these costs affect the initiation of novel treatments,
the authors analyzed claims data for patients covered by commercial insurance
or Medicare Part D who received a new prescription for any of 38 oral
anticancer medications from 2014-2015. These claims data were unique in that
they included all prescriptions approved by the payer, including those that the
patient opted not to fill, along with the amount due from the patient at the
time of pickup after coupons or copayment assistance were applied.

Adjusting for socioeconomic and clinical characteristics, the authors found
that rates of abandonment and delay increased as the OOP cost category
increased, in a linear fashion. As shown in Figure 1, nearly half of patients
(49%) facing OOP costs over $2,000 abandoned their prescription, whereas
only 10% of patients facing OOP costs of less than $10 did. Among patients
in the lowest OOP cost category, only 3% delayed filling their prescription,
compared with 18% in the highest OOP cost category. The average delay
was 35 days, which was similar across all OOP cost categories.
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The findings also point to the need for timely patient-provider conversations
to evaluate any alternate, lower OOP cost treatment options. This is
especially important with self-administered treatments, where initiation delay
and nonadherence are more difficult to monitor. As the availability of oral
anticancer treatment options continues to increase, access and affordability
will determine the true benefit for patients. All stakeholders – including
manufacturers, pharmacy benefit managers, payers, and policymakers – must
work to identify fiscally sustainable strategies to improve patient access to
cancer medications.

FIGURE 1.
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These patterns were consistent across cancers. Although abandonment rates
were highest for medications to treat metastatic cancers that typically have
poorer prognosis, a substantial percentage of patients abandoned treatment
even for cancers where the medication has been shown to extend life by
many years.
The authors used these risk-adjusted rates to simulate how abandonment
might change in light of ongoing trends toward higher OOP costs. This
simulation revealed that if patients currently responsible for $50 to $100 per
prescription were shifted to the next higher OOP cost category ($100 to
$500), abandonment rates would likely double (from 16% to 36%).

THE IMPLICATIONS
This study raises questions about whether patients will be able to take
advantage of new cancer treatments. Currently, OOP costs greater than
$2,000 for a new oral cancer medication are typical for Medicare Part D
patients without low-income subsidies and for many commercially insured
patients. Given the study’s focus on new treatment episodes, these findings
suggest that financial barriers may limit patient access to what may be the
provider’s and/or patient’s first choice medication. Such obstacles may
impose additional financial burdens and inflict emotional stress at a time
when patients are already coping with a life-altering diagnosis or change in
medical status.

This retrospective, claims-based analysis used data from a large, proprietary,
integrated database that includes point-of-sale prescription purchase
information detailing the patient’s OOP liability (after application of coupons
or copay assistance) and final claim payment status (paid or reversed claim).
The final sample included 38,111 patients with a new, payer-approved
prescription for any of 38 oral anticancer medications between 2014-2015.
The authors tracked whether patients filled their prescription after it was
approved by the insurer, and if not (i.e., the claim was reversed), whether
the prescription was filled with a delay (within 90 days) or abandoned
completely. The authors also examined whether patients who abandoned
their prescription initiated alternate treatment from the same drug class,
including intravenous therapies, in the following 90 days. They adjusted for
other relevant factors, including type of insurance, type of pharmacy, and
patient characteristics, and explored differences for several patient subgroups
(by insurance coverage, pharmacy type, sex, and indication).
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